Pfizer and BioNTech's Combo Shot Missed the Mark. Is It Time to Sell?
(NYSE: PFE) and BioNTech (NASDAQ: BNTX) recently fell behind in their race with Moderna (NASDAQ: MRNA) to develop new combination shots that could be worth billions in annual sales. Top-line results from an experimental vaccination to protect against influenza and COVID-19 weren't a complete disaster, but there isn't much room for error when it comes to vaccine development.
A late-stage clinical-trial setback is bad news, but that doesn't necessarily mean it's a good idea to sell any shares of Pfizer or BioNTech right now. Here's what shareholders from both companies need to know before making any rash decisions based on one clinical-trial outcome.
Pfizer and BioNTech enrolled more than 8,000 healthy adults into a phase 3 trial with an mRNA vaccine candidate built to protect against influenza and COVID-19. The combo shot contains the partners' COVID-19 vaccine, which has already been given to millions, plus Pfizer's experimental mRNA influenza vaccine.
Source Fool.com
Pfizer Inc. Stock
The stock is one of the favorites of our community with 32 Buy predictions and 4 Sell predictions.
As a result the target price of 41 € shows a very positive potential of 57.69% compared to the current price of 26.0 € for Pfizer Inc..
